Other Clinical Trial - AZA Combined With NAC for PIT After HSCT

Status Not yet recruiting

Clinical Trial Summary

Prolonged isolated thrombocytopenia (PIT) that is refractory to conventional treatments has remained a critical complication after allogeneic hematopoietic cell transplantation since decades years ago. Recombinant human thrombopoietin (rhTPO) is the main therapy in clinical practice, but remains low efficiency for PIT. Demethylating drugs have shown thier potential in high-risk myelodysplastic syndromes (MDS) and acte myeloid leukemia (AML). In addition, decitabine has demonstrated its efficacy of over 70% for response rate in treatment for PIT in early clinical trials with elusive mechanism. Preliminary experiments revealed that PIT was associated with abnormality of oxidation microenvironment, and N-Acetyl-L-cysteine (NAC) was the most commonly used antioxidant. Therefore, the investigators have been wondering whether Azacitidine in combination with NAC could improve PIT post HSCT and explore the possible mechanism of it.

Clinical Trial Description

Prolonged isolated thrombocytopenia (PIT) that is refractory to conventional treatments has remained a critical complication after allogeneic hematopoietic cell transplantation since decades years ago. Recombinant human thrombopoietin (rhTPO) is the main therapy in clinical practice, but remains low efficiency for PIT. Demethylating drugs have shown thier potential in high-risk myelodysplastic syndromes (MDS) and acte myeloid leukemia (AML). In addition, decitabine has demonstrated its efficacy of over 70% for response rate in treatment for PIT in early clinical trials with elusive mechanism. Preliminary experiments revealed that PIT was associated with abnormality of oxidation microenvironment, and N-Acetyl-L-cysteine (NAC) was the most commonly used antioxidant. Furthermore, AZA had shown its potential in immune regulation. Therefore, the investigators have been wondering whether Azacitidine in combination with NAC could improve PIT post HSCT and explore the possible mechanism of it. ;

Study Design

Related Conditions & MeSH terms

Stem Cell Transplant Complications
Thrombocytopenia

Clinical Trial Details

NCT number	NCT05126004
Study type	Interventional
Source	The First Affiliated Hospital of Soochow University
Contact	Yue Han, PhD,MD
Phone	0512-67781856
Email	hanyue@suda.edu.cn
Status	Not yet recruiting
Phase	Phase 2
Start date	December 1, 2021
Completion date	June 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03482154` - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Recruiting	`NCT06080490` - Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients
Completed	`NCT03042676` - Electronic Database for the Follow up of the ATG_FamilyStudy
Recruiting	`NCT03871296` - DNA Methylation in Allogeneic Hematopoietic Stem Cell Transplantation.
Not yet recruiting	`NCT06022445` - Prospective Validation of CARPET Prognostic Model for Septic Shock After Allo-HSCT
Recruiting	`NCT04502628` - Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT	N/A
Recruiting	`NCT03793517` - Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT	Phase 2/Phase 3
Completed	`NCT03454568` - The Patients' Experience After Stem Cell Transplant
Recruiting	`NCT05466201` - The Use of Eltrombopag Post HSCT in BMFS	Phase 2/Phase 3
Not yet recruiting	`NCT04080622` - Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation.	Phase 3
Recruiting	`NCT05523336` - Pro-ADM vs PCT in Patients With Complications Post Hematopoietic Stem Cell Transplantation
Completed	`NCT03355235` - Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant
Completed	`NCT04888286` - DSAs in Patients Undergoing Allo-HSCT From Mismatched Donors
Not yet recruiting	`NCT05421416` - Loratadine for the Prevention of G-CSF-related Bone Pain	Phase 2
Recruiting	`NCT04167683` - Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
Active, not recruiting	`NCT03967665` - Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution	Phase 3
Withdrawn	`NCT05104268` - Study of a New Medical Device for Oral Mucositis	Early Phase 1
Recruiting	`NCT04623424` - Intestinal Microbiota in Stem Cell Transplant Transplant Admission
Active, not recruiting	`NCT04669210` - PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT	Phase 2
Completed	`NCT03489551` - Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.